CD4 and cancer: Therefore, it is important to provide a comprehensive overview of the BTN3A molecule’s effect on CD8 T cells, CD4 (Th1) T cells, and NK cells, summarize differential prognoses, clinical implications, therapeutic potential, and downstream signaling cascades based on the cellular contexts of BTN3A molecules in cancers.